Thrivent Financial for Lutherans Sells 2,053 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Thrivent Financial for Lutherans lessened its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 7.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,402 shares of the company’s stock after selling 2,053 shares during the period. Thrivent Financial for Lutherans’ holdings in Harmony Biosciences were worth $797,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC grew its position in shares of Harmony Biosciences by 23.4% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 15,556 shares of the company’s stock valued at $502,000 after acquiring an additional 2,953 shares during the period. Cim LLC purchased a new stake in shares of Harmony Biosciences during the 4th quarter valued at about $368,000. Los Angeles Capital Management LLC raised its position in shares of Harmony Biosciences by 4.5% during the 1st quarter. Los Angeles Capital Management LLC now owns 25,224 shares of the company’s stock valued at $847,000 after buying an additional 1,076 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Harmony Biosciences by 1.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 35,272 shares of the company’s stock valued at $1,184,000 after buying an additional 397 shares in the last quarter. Finally, Hedeker Wealth LLC purchased a new stake in shares of Harmony Biosciences during the 1st quarter valued at about $2,627,000. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

NASDAQ:HRMY opened at $34.38 on Tuesday. The company’s 50-day moving average price is $36.09 and its 200-day moving average price is $32.71. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32. The company has a market cap of $1.95 billion, a P/E ratio of 14.88, a P/E/G ratio of 0.77 and a beta of 0.73. Harmony Biosciences Holdings, Inc. has a twelve month low of $18.61 and a twelve month high of $40.60.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.24. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The firm had revenue of $172.80 million for the quarter, compared to the consensus estimate of $172.53 million. During the same period last year, the firm posted $0.56 earnings per share. The company’s revenue for the quarter was up 28.8% on a year-over-year basis. On average, sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a report on Wednesday, October 2nd. Citigroup assumed coverage on shares of Harmony Biosciences in a research report on Friday, June 21st. They set a “buy” rating and a $48.00 target price for the company. Finally, UBS Group assumed coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They set a “buy” rating and a $56.00 target price for the company. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.